PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
Maher Abdul-Hay,
Courtney Dinardo,
Onyee Chan,
Rupa Narayan,
Ghayas Issa,
Jennifer Michaelson,
Patrick Baeuerle,
Kristan Meetze,
John Janik,
Irina Shapiro,
Judy Inumerable,
Jeffery Jones,
David Sallman
Affiliations
Maher Abdul-Hay
1 New York University Langone Health, Blood and Marrow Transplantation and Cellular Therapy, New York, United States
Courtney Dinardo
2 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States
Onyee Chan
3 H. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, United States
Rupa Narayan
4 Mass General Cancer Center, Department of Hematology/Oncology, Cambridge, United States
Ghayas Issa
2 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States
Jennifer Michaelson
5 Cullinan Oncology, Cambridge, United States
Patrick Baeuerle
5 Cullinan Oncology, Cambridge, United States
Kristan Meetze
5 Cullinan Oncology, Cambridge, United States
John Janik
5 Cullinan Oncology, Cambridge, United States
Irina Shapiro
5 Cullinan Oncology, Cambridge, United States
Judy Inumerable
5 Cullinan Oncology, Cambridge, United States
Jeffery Jones
5 Cullinan Oncology, Cambridge, United States
David Sallman
3 H. Lee Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, United States
